SLC5A2 and type 1 diabetes mellitus: Although sotagliflozin, as a dual SGLT1 and SGLT2 inhibitor, has been administered as an addition to insulin therapy in patients with type 1 diabetes, improvements not only in glycemic control but also in body weight and blood pressure regulation were described.